Magic

[MWM]

Lenzilumab
Developer: Humanigen
FDA Status: Application Submitted
Patients: Hospitalized kids and adults
Humanigen’s monoclonal antibody, lenzilumab, hasn’t yet been granted Emergency Use Authorization by the FDA — but the decision could come any day. On May 28th, the company announced that it had submitted an application for the drug to get FDA authorization for use as a treatment in hospitalized adults and kids. Like Actemra, lenzilumab is not specifically an anti-Covid body. It’s another anti-inflammatory antibody, which is being developed as a treatment for cytokine storms that can affect patients who are undergoing treatments like CAR-T cell therapy, as well as Covid-19. Unlike Actemra, which is used for hospitalized patients that are already on ventilation, Humanigen’s drug is used for patients who are newly hospitalized with Covid-19, but not yet on mechanical ventilators. In clinical trials, patients who took lenzilumab had a 54% relative improvement in the likelihood of surviving without ventilation compared to patients who got a placebo medication. Paired with other drugs, including steroids and remdesivir, the chance of avoiding ventilation was even higher. If authorized, this treatment could prove to do a lot to keep people from dying from a Covid infection.

https://www.forbes.com/sites/leahrosenbaum/2021/07/01/there-are-four-covid-antibody-therapies-on-the-market-and-one-close-to-it-heres-how-they-compare/?sh=4e2007444b62